Celgene Corporation (CELG) : Investors lapped up stocks on upticks to the tune of $38.36 million in the Fridays trading session. The trading value on downticks was comparatively at $30.15 million and the uptick to downtick ratio of 1.27 indicates continuous buying by the bulls. The net money flow into the stock was $8.21 million. The block trades were dominated by the bulls with a healthy 6.75, uptick to downtick ratio. Only $1.7 million worth of trades exchanged hands on downticks showing the reluctance of the large traders to part with their holdings. Upticks saw transactions worth $11.48 clearly indicating buying by large investors. The total money flow for block trades stood at $9.78 million, which is a positive for the stock in the long-term. Celgene Corporation (CELG) fell $0.01 during the day at $107.44, a drop of -0.01% over the previous days close. However, for the week, the stock is 4.46%, compared to the previous week.
Celgene Corporation (CELG) has been rated by 15 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $162 and the lowest price target forecast is $120. The average forecast of all the analysts is $142.07 and the expected standard deviation is $13.55.
Celgene Corporation (NASDAQ:CELG): stock turned positive on Friday. Though the stock opened at $107.98, the bulls momentum made the stock top out at $108.4 level for the day. The stock recorded a low of $106.75 and closed the trading day at $107.52, in the green by 0.07%. The total traded volume for the day was 3,480,242. The stock had closed at $107.45 in the previous days trading.
In a related news, The Securities and Exchange Commission has divulged that Hugin Robert J, director officer (see remarks) of Celgene Corp /De/, had unloaded 75,000 shares at an average price of $100.16 in a transaction dated on June 20, 2016. The total value of the transaction was worth $7,512,000.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.